[Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?]

Endocrinol Nutr. 2010 Dec;57(10):457-9. doi: 10.1016/j.endonu.2010.05.010. Epub 2010 Aug 4.
[Article in Spanish]
No abstract available

Publication types

  • Comparative Study
  • Editorial

MeSH terms

  • Aged
  • Atherosclerosis / etiology
  • Atherosclerosis / prevention & control
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / prevention & control
  • Diabetes Complications / drug therapy*
  • Diabetes Mellitus, Type 2 / complications
  • Drug Therapy, Combination
  • Dyslipidemias / drug therapy*
  • Female
  • Fenofibrate / administration & dosage
  • Fenofibrate / therapeutic use*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hypolipidemic Agents / administration & dosage
  • Hypolipidemic Agents / therapeutic use*
  • Male
  • Middle Aged
  • Multicenter Studies as Topic / statistics & numerical data*
  • Practice Guidelines as Topic
  • Randomized Controlled Trials as Topic / statistics & numerical data*
  • Simvastatin / administration & dosage
  • Simvastatin / therapeutic use*

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypolipidemic Agents
  • Simvastatin
  • Fenofibrate